



HAL
open science

Analysis of Lipid Peroxidation by UPLC-MS/MS and Retinoprotective Effects of the Natural Polyphenol Pterostilbene

Isabel Torres-Cuevas, Iván Millán, Miguel Asensi, Máximo Vento, Camille Oger, Jean-Marie Galano, Thierry Durand, Ángel Ortega

► To cite this version:

Isabel Torres-Cuevas, Iván Millán, Miguel Asensi, Máximo Vento, Camille Oger, et al.. Analysis of Lipid Peroxidation by UPLC-MS/MS and Retinoprotective Effects of the Natural Polyphenol Pterostilbene. *Antioxidants*, 2021, 10 (2), pp.168. 10.3390/antiox10020168. hal-03448850

HAL Id: hal-03448850

<https://hal.science/hal-03448850>

Submitted on 25 Nov 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution 4.0 International License



Article

Analysis of Lipid Peroxidation by UPLC-MS/MS and Retinoprotective Effects of the Natural Polyphenol Pterostilbene

Isabel Torres-Cuevas ¹, Iván Millán ¹, Miguel Asensi ², Máximo Vento ¹, Camille Oger ³, Jean-Marie Galano ³, Thierry Durand ³ and Ángel L. Ortega ^{2,*}

- ¹ Neonatal Research Group, Health Research Institute La Fe, Av. Fernando Abril Martorell 106, 46026 Valencia, Spain; maria.i.torres@uv.es (I.T.-C.); imiya@alumni.uv.es (I.M.); maximo.vento@uv.es (M.V.)
- ² Department of Physiology, Faculty of Pharmacy, University of Valencia, Vicente Andrés Estellés Av. s/n, 46100 Burjassot, Spain; Miguel.A.Asensi@uv.es
- ³ Institut des Biomolécules Max Mousseron, IBMM, University of Montpellier, CNRS, ENSCM, 34093 Montpellier, France; camille.oger@umontpellier.fr (C.O.); jean-marie.galano@umontpellier.fr (J.-M.G.); thierry.durand@umontpellier.fr (T.D.)
- * Correspondence: angel.ortega@uv.es; Tel.: +34-963543817

Abstract: The loss of redox homeostasis induced by hyperglycemia is an early sign and key factor in the development of diabetic retinopathy. Due to the high level of long-chain polyunsaturated fatty acids, diabetic retina is highly susceptible to lipid peroxidation, source of pathophysiological alterations in diabetic retinopathy. Previous studies have shown that pterostilbene, a natural antioxidant polyphenol, is an effective therapy against diabetic retinopathy development, although its protective effects on lipid peroxidation are not well known. Plasma, urine and retinas from diabetic rabbits, control and diabetic rabbits treated daily with pterostilbene were analyzed. Lipid peroxidation was evaluated through the determination of derivatives from arachidonic, adrenic and docosahexaenoic acids by ultra-performance liquid chromatography coupled with tandem mass spectrometry. Diabetes increased lipid peroxidation in retina, plasma and urine samples and pterostilbene treatment restored control values, showing its ability to prevent early and main alterations in the development of diabetic retinopathy. Through our study, we are able to propose the use of a derivative of adrenic acid, 17(RS)-10-*epi*-SC- Δ^{15} -11-dihomo-IsoF, for the first time, as a suitable biomarker of diabetic retinopathy in plasmas or urine.

Keywords: diabetic retinopathy; lipid peroxidation; oxidative stress; polyphenols; pterostilbene; biomarker



Citation: Torres-Cuevas, I.; Millán, I.; Asensi, M.; Vento, M.; Oger, C.; Galano, J.-M.; Durand, T.; Ortega, Á.L. Analysis of Lipid Peroxidation by UPLC-MS/MS and Retinoprotective Effects of the Natural Polyphenol Pterostilbene. *Antioxidants* **2021**, *10*, 168. <https://doi.org/10.3390/antiox10020168>

Academic Editors: Vanessa Routh and Xavier Fioramonti

Received: 10 December 2020

Accepted: 20 January 2021

Published: 23 January 2021

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Diabetes is a disease with high social impact and multiple systemic consequences. The prevalence of this disease has increased from 285 million to 463 million in the last decade and is expected to rise to 700 million in 2045 [1,2]. However, many diabetic cases are not strictly controlled until the pathology is at an advanced stage, with the loss of metabolic control leading to the development of long-term damages related to neurological, micro- and macrovascular alterations in different body organs, such as the retina. In fact, diabetic retinopathy (DR) is the most frequent ocular pathology caused by diabetes and the main cause of preventable blindness cases in economically active people (20–65 years) [3].

The presence of the blood-retina barrier means the retina is well protected from the leakage of circulating blood toxins. However, this tissue is extremely sensitive to alterations in oxygen levels [4]. Under chronic hyperglycemia, redox homeostasis is severely impaired and the overproduction of reactive oxygen species triggers neuronal and vascular damage, critical processes in the DR development [3]. Hyperglycemia induces alterations in biochemical pathways such as the polyol pathway, increased flux of advanced glycation end products/receptors (AGE/RAGE), and the hexosamine pathway which

contributes to an oxidizing environment and triggers a state of low chronic inflammation leading to progression of DR to advanced stages [3]. Moreover, the delay in the treatment of diabetes together with the accumulated molecular damage inflicted by oxidative stress enables the phenomenon of metabolic memory, which refers to the development of DR even though there is good late glycemic control [5].

Polyphenols are secondary metabolites of plants with high antioxidant properties. In fact, the benefit of polyphenols has been suggested for combatting diabetes complications such as DR [3,6,7]. Pterostilbene (Pter), a natural analog of resveratrol, has recently been proposed as an inhibitor of aldose reductase, the rate-limiting enzyme of the polyol pathway, and AGE production [8], besides, it was able to reduce the levels of hexose and hexosamine in plasma, hepatic, and renal tissues to control values in diabetic animals [9], showing the polyphenol as a possible therapeutic agent against long-term complications of diabetes. Our group showed that parenteral daily administration of Pter, trans-3,5-dimethoxy-4'-hydroxystilbene, protected alloxan-induced diabetic rabbits by attenuating hyperglycemia-mediated oxidative stress via PI3K/AKT/GSK3 β /NRF2 pathway [7]. The stilbene reduced lipid and protein oxidative damage, stimulated the activity of superoxide dismutase, catalase and glutathione peroxidase and increased GSH levels in the retina with a reduction in oxidative stress preventing early DR alterations [7].

The retina is one of the body tissues with the highest concentration of long-chain polyunsaturated fatty acids (PUFAs), the latter being essential for the maintenance of the physiological retinal function and development [10,11]. There is increasing evidence of the importance of lipids as mediators in the development of different retinal pathologies. In fact, the alteration of the lipid profile of patients is determinant in the progression of DR [12] and lipid peroxidation end product such as 4-hydroxy-2,3-trans-nonenal (4-HNE) alters the lysosomal functionality generating lipofuscin accumulation [13]. Based on these evidences, we hypothesize that Pter reverses the lipid oxidation profile induced in retinas under chronic hyperglycemia in vivo and that these changes may be reflected in plasma and urine becoming a potential biomarker for early detection of pathology.

2. Materials and Methods

2.1. Animal Model

In this study, male New Zealand rabbits obtained from Granja San Bernardo, Navarra, Spain were used. All procedures were performed according to established criteria by the Ethics Committee for Animal Experimentation and Welfare of the University of Valencia (Spain) (ethical code number of animal use 2016/VSC/PEA/00198, Generalitat Valenciana). Housing conditions and experimental procedures were in accordance with European Union (Directive 2010/63/EU) and Spanish (Royal Decree 53/2013) regulations.

Rabbits were randomly divided into 3 groups: control (non-diabetic), diabetic (diabetic), and treated diabetic (treated). In the experimental groups (diabetic and treated), diabetes was induced with alloxan (Sigma-Aldrich, St. Louis, MO, USA) following the protocol described by Alabadí et al. [14]. Briefly, animals were sedated with intramuscular injection of ketamine (Ketalar[®], Pfizer Inc., Richmond, VA, USA) (35 mg/kg) and xylazine (Dechra Pharmaceuticals PLC, Northwich, UK) (5 mg/kg). Next, diabetes was induced by injecting alloxan (100 mg/kg) into the marginal ear vein. In addition, to prevent hypoglycemia, 5% glucose (Sigma-Aldrich, St. Louis, MO, USA) (10 mL) was administered intravenously, and drinking water was supplemented with 10% glucose for 24 h. In the case of the group of treated rabbits, Pter treatment began 48 h after inducing diabetes. The isotonic solution of Pter phosphate disodium salt (Syncom, Groningen, The Netherlands) was subcutaneously administered to treated diabetic animals daily (74 mg/kg which is equal to 50 mg/kg of Pter). Animals were euthanized by intravenous administration of sodium pentobarbital (Vetoquinol, Madrid, Spain) (100 mg/kg) 6 weeks after diabetes induction.

2.2. Standards and Reagents

Methanol, NaOH, KOH, ethanol, heptane, acetonitrile and ethyl acetate (analytical grade) were purchased from Sigma (Sigma-Aldrich, St. Louis, MO, USA). The formic acid and HCl were from Panreac (Barcelona, Spain) and Ultrapure H₂O was generated on a milliQ system from Millipore.

Lipid oxidative damage was determined by the analysis of prostaglandines (PG), isoprostanes (IsoP), neuroprostanes (NeuroP), dihomom-IsoP, and dihomom-isofurans (dihomom-IsoF) using ultra high-performance liquid chromatography mass spectrometry (UPLC-MS/MS) (Waters Acquity UPLC-XevoTQ system, Milford, MA, USA). The analysis was carried out on different biological matrices: retina, plasma and urine.

The prostaglandin standard PGE₂, PGF_{2 α} , the IsoP standards 8-*iso*-PGE₂, 8-*iso*-15-keto-PGE₂, 8-*iso*-PGF_{2 α} (also named 15-F_{2t}-IsoP), 8-*iso*-15-keto-PGF_{2 α} , 8-*iso*-15(R)-PGF_{2 α} , 5-*iso*-PGF_{2 α} -VI, 2,3-dinor-8-*iso*-PGF_{2 α} , 1a,1b-dihomom-PGF_{2 α} , and deuterated internal standard PGF_{2 α} -d₄ were obtained from Cayman Chemical Company (Ann Arbor, MI, USA) (Figure 1). The standards 10-*epi*-10-F_{4t}-NeuroP, 4(RS)-4-F_{4t}-NeuroP, 14(RS)-14-F_{4t}-NeuroP, 17-F_{2t}-dihomom-IsoP, Ent-7(RS)-7-F_{2t}-dihomom-IsoP, 17-*epi*-17-F_{2t}-dihomom-IsoP, 17(RS)-10-*epi*-SC- Δ ¹⁵-11-dihomom-IsoF, 7(RS)-ST- Δ ⁸-11-dihomom-IsoF were synthesized at the Institute of Biomolecules Max Mousseron (IBMM) (Montpellier, France) by Professor Durand's team [15] (Figure 1).

2.3. Retina Sample Analysis

Animals were sacrificed as mentioned above, by intravenous administration of sodium pentobarbital. Subsequently, ocular enucleation was performed, and the retinas were separated into two halves and stored in cryotubes at -80 °C until further analysis. Approximately 30–50 mg of retina was stored for 30 min at 42 °C with 1 mL of methanolic NaOH (12 g of NaOH, 23 mL of H₂O and 160 mL of MeOH). Then, they were homogenized and transferred to a glass tube, in which 400 μ L of homogenate, 800 μ L of H₂O, 400 μ L of methanolic NaOH and 5 μ L of internal standard (PGF_{2 α} -d₄ 20 μ M) were added, and then heated for 45 min at 42 °C to produce saponification. The samples were then cooled on ice for 10 min. Subsequently, for protein precipitation, the pH of the sample was adjusted to 3 with HCl (3 M) and centrifuged at 3000 \times g. Once the supernatant was obtained, L/L extractions were carried out to extract the IsoP with 3 mL of hexane. It was centrifuged again for 5 min at 3000 \times g. The organic phase was removed, and 3 mL of ethyl acetate were added to the IsoP extract and centrifuged. The supernatant was collected in another container and evaporated with nitrogen gas in a hood at 40 °C. After this, the dry extracts were reconstituted in 200 μ L of H₂O (pH 3, 0.1% *v/v* CH₃COOH):CH₃OH (85:15 *v/v*). During the sample treatment, glass material such as glass tube and Pasteur pipette was used. This solution was analyzed by UPLC-MS/MS. The results were standardized by the protein levels measured in the retinal homogenates using the Pierce BCA protein assay kit (Fisher Scientific, Madrid, Spain) following the manufacturer's protocol.

2.4. Plasma Sample Analysis

Blood samples were collected through the central atrial artery of the ears in heparinized tubes at the time of sacrifice and were processed within 30 min after extraction. The samples were centrifuged for 10 min at 1000 \times g at room temperature, and the supernatant (plasma) was separated and aliquoted. Thereafter, samples were stored at -80 °C until analysis.

A volume of 200 μ L of plasma samples was thawed at 4 °C and 5 μ L of internal standard solution (20 μ M) was added. Plasma samples were subjected to basic hydrolysis by adding 200 μ L of 15% KOH solution (*w/v*). The mixture was incubated at 40 °C for 30 min. Thereafter, samples were diluted with 1360 μ L of H₂O (pH 3, 0.1% *v/v* HCOOH):MeOH (85:15), acidified with 40 μ L of formic acid, placed on ice for 10 min, and centrifuged at 4000 \times g for 10 min at 4 °C. The supernatant was collected and a cleaning and preconcentration step was performed using solid phase extraction (SPE). This was performed

to achieve a higher concentration of the analytes, using SPE-96 well plates (Discovery® DSC-18, Sigma-Aldrich, St. Louis, MO, USA). SPE cartridges were conditioned first with 1 mL of methanol and then with 1 mL of H₂O (pH 3, 0.1% *v/v* HCOOH). Samples were added in SPE wells, and each well was washed with 500 µL H₂O (pH 3, 0.1% *v/v* HCOOH) and 500 µL heptane. Elution was carried out with 4 × 100 µL ethyl acetate in 96-well sample plates (Acquity UPLC 700 µL, from Waters, Barcelona, Spain). The recovered samples were evaporated in a speed vacuum concentrator (Savant SPD111V, Thermo Scientific, Waltham, MA, USA) at 45 °C. Finally, the extracts were reconstituted in 60 µL of H₂O (pH 3, 0.1% *v/v* HCOOH): CH₃OH (85:15 *v/v*) and measured in the UPLC–MS/MS.

2.5. Urine Sample Analysis

For the analysis of the samples, 1 mL of urine was used. The samples were thawed at 4 °C and centrifuged at 14,000 × *g* for 10 min at 4 °C. The supernatant was collected and 5 µL of internal standard solution (20 µM) was added. Then an SPE and elution in ethyl acetate were performed in the same way as for the retina samples in order to achieve a higher concentration of the analytes. Once evaporated, the dry extracts were reconstituted in 100 µL of H₂O (pH 3, 0.1% *v/v* HCOOH):CH₃OH (85:15 *v/v*). Finally, they were injected into the chromatographic system (UPLC-MS/MS).

Results were standardized by creatinine levels measured using a creatinine assay (MicroVue creatinine EIA, Quidel Corporation, San Diego, CA, USA) according to the manufacturer's instructions.

Validation of the bioanalytical method in plasma and urine has been shown in previous studies [16] and the guidelines of the United States Food and Drug Administration were followed [17].

2.6. UPLC-MS/MS Analysis

UPLC-MS/MS analysis was carried out on an Acquity-Xevo TQ system (Waters, Barcelona, Spain). The conditions used were: ionization in negative mode (ESI-), capillary voltage 3.5 kV, source temperature 120 °C, desolvation temperature 300 °C, gas flow of the nitrogen cone of 150 L/h, and desolvation flow of 680 L/h.

Separation conditions were selected to achieve appropriate chromatographic retention and resolution by using a C18 column (2.1 × 50 mm, 1.7 µm) (Acquity UPLC BEH) and pre-column (2.1 × 5 mm) from Waters. A binary mobile phase CH₃OH (0.1% *v/v* HCOOH):H₂O (0.1% *v/v* HCOOH) with gradient elution was used. The flow rate was 0.4 mL/min, the temperatures of column and the autosampler were 37 °C and 4 °C, respectively. The injection volume was 10 µL. The gradient started with 30% *v/v* CH₃OH (0.1% *v/v* HCOOH) (i.e., channel B) and from 1 to 4.0 min %B increased up to 90%. Finally, the mobile phase composition returned to the initial conditions at 4.1, and it was maintained for 3.9 min for system conditioning.

The detection was performed by multiple reaction monitoring using the acquisition parameters obtained in a previous study [18,19].

For data acquisition and processing, MassLynx 4.1 and QuanLynx 4.1 softwares from Waters (Waters, Barcelona, Spain) were used, respectively. Linear response curves were calculated employing PGF_{2α}-d₄ as internal standard.

2.7. Statistical Analyses

All values in retina, plasma and urine were expressed as median (inter-quartile range, IQR). A one-way ANOVA was employed to determine the differences among groups, followed by Tukey's multiple comparison test. The null hypothesis was rejected for all the values in the tests in which the F value was significant with a *p*-value less than 0.05. Statistical analyses were performed using Prism 5.0 for Windows software (GraphPad Software, San Diego, CA, USA).




Figure 1. Chemical structure of analytes and internal standard. The analyzed PUFAs derived from arachidonic acid, adrenic acid and docosahexaenoic acid through cyclooxygenase (COX) pathway and/or non-enzymatic peroxidation are separated in different color boxes.

3. Results

3.1. Pterostilbene Reduces Harmful Retinal Lipid Oxidation Induced by Chronic Hyperglycemia In Vivo

It is well-known that chronic hyperglycemia is a potent inductor of reactive oxygen species. In a recent study, using the current experimental model, we showed that hyperglycemia induces very early lipid oxidation in retina tissue of diabetic animals [7]. In addition, our group showed the ability of Pter to lower lipid peroxidation evaluated by 4-hydroxy-2-nonenal levels in diabetic treated animals [7]. Here we look more in depth at retinal lipids oxidation under diabetes. As shown in Figure 2, chronic hyperglycemia increases lipid peroxidation on arachidonic, adrenic and docosahexaenoic acids in retinal samples. Specifically, we detected significant increases in the values of the prostaglandins PGE₂ and PGF_{2α}, and the IsoPs 8-iso-PGE₂, 8-iso-15-keto-PGF_{2α}, and 8-iso-15-(R)-PGF_{2α} (Figure 2A). Oxidation on adrenic acid was reflected by a significant increase in 17-F_{2t}-dihomo-IsoP, Ent-7(RS)-7-F_{2t}-dihomo-IsoP, 17-epi-17-F_{2t}-dihomo-IsoP, and 17(RS)-10-epi-SC-Δ¹⁵-11-dihomo-IsoF (Figure 2B). Similar results were obtained for docosahexaenoic acid oxidation which was reflected in an increase of 10-epi-10-F_{4t}-NeuroP, 4(RS)-4-F_{4t}-NeuroP and 14(RS)-14-F_{4t}-NeuroP (Figure 2C). As we expected, subcutaneous daily administration of Pter was able to reverse these early oxidative alterations (Figure 2).

3.2. Determination of Lipid Oxidation Analytes in Plasma and Urine in an Experimental Diabetes Type 1 Model

Diabetes is a systemic disease meaning that it can affect different body organs, and logic suggests that any physiological changes in these organs would be reflected in plasma and urine, since the internal medium is in constant motion between the interstitial fluid and the plasma, as well as in the circulatory system. Hence, analyses of plasma samples clearly showed lipid oxidation levels in diabetic rabbits (Figure 3). Analytes derived from arachidonic acid such as PGE₂, PGF_{2α}, 8-iso-PGF_{2α}, 8-iso-15-keto-PGF_{2α}, 8-iso-15(R)-PGF_{2α} increased (Figure 3A). Likewise, the levels of 8-iso-15-keto-PGE₂, which were non-detected in retina tissue, showed a significant increase in plasma of diabetic animals (Figure 3A). We found that 8-iso-PGE₂ presented undetectable changes between control, diabetic and treated animals (Figure 3A). Lipid oxidation was also reflected in the levels of the adrenic acid derivatives 17-F_{2t}-dihomo-IsoP, 17-epi-17-F_{2t}-dihomo-IsoP, and 17(RS)-10-epi-SC-Δ¹⁵-11-dihomo-IsoF (Figure 3B) and an increase of docosahexaenoic acid oxidative product 10-epi-10-F_{4t}-NeuroP in diabetic rabbit plasma samples (Figure 3C).

The antioxidant capability of Pter was demonstrated in a limited number of lipid oxidation analytes in plasma. In Figure 3, we show that treatment with polyphenol is able to lower PGE₂, 8-iso-15-keto-PGE₂, 8-iso-15-keto-PGF_{2α}, 8-iso-15(R)-PGF_{2α} (Figure 3A), 17(RS)-10-epi-SC-Δ¹⁵-11-dihomo-IsoF (Figure 3B), and 10-epi-10-F_{4t}-NeuroP (Figure 3C).

Diabetes-induced lipid oxidation was reflected in urine in an increase of derivatives of arachidonic acid: PGE₂, PGF_{2α}, 8-iso-15-keto-PGE₂, 8-iso-PGF_{2α}, 5-iso-PGF_{2α}-VI, and 2,3-dinor-8-iso-PGF_{2α} were increased (Figure 4A). In addition, the levels of the adrenic acid products 17-F_{2t}-dihomo-IsoP, Ent-7(RS)-7-F_{2t}-dihomo-IsoP, 17(RS)-10-epi-SC-Δ¹⁵-11-dihomo-IsoF, and 7(RS)-ST-Δ⁸-11-dihomo-IsoF were also increased (Figure 4B). In a similar way, lipid peroxidation of docosahexaenoic acid induced an increase of 14(RS)-14-F_{4t}-NeuroP and 4(RS)-4-F_{4t}-NeuroP levels in urine samples (Figure 4C). The levels of all analytes with significant diabetes-induced changes were normalized with the polyphenol treatment (Figure 4).




Figure 2. Boxplots of lipoperoxidation analytes in retina samples from control, diabetic and treated group. Lipid peroxidation compounds derived from (A) arachidonic acid, (B) adrenic acid and (C) docosahexaenoic acid. Boxes indicate the 1st and the 3rd quartiles, the median is shown as a black line, whiskers mark the maximum and the minimum values. Values below the limit of detection were replaced by the number of quantification limit indicated by (<LD). The statistical difference is indicated as * < 0.05 vs. control, ** < 0.01 vs. control, & < 0.05 vs. diabetic, && < 0.01 vs. diabetic.




Figure 3. Boxplots of lipoperoxidation analytes in plasma samples from control, diabetic and treated group. Lipid peroxidation compounds derived from (A) arachidonic acid, (B) adrenic acid and (C) docosahexaenoic acid. Boxes indicate the 1st and the 3rd quartiles, the median is shown as a black line, whiskers mark the maximum and the minimum values. Values below the limit of detection were replaced by the number of quantification limit indicated by (<LD). The statistical difference is indicated as * < 0.05 vs. control, ** < 0.01 vs. control, *** < 0.001 vs. control, & < 0.05 vs. diabetic, && < 0.01 vs. diabetic, &&& < 0.001 vs. diabetic.




Figure 4. Boxplots of lipoperoxidation analytes in urine samples from control, diabetic and treated group. Lipid peroxidation compounds derived from (A) arachidonic acid, (B) adrenic acid and (C) docosahexaenoic acid. Boxes indicate the 1st and the 3rd quartiles, the median is shown as a black line, whiskers mark the maximum and the minimum values. Values below the limit of detection were replaced by the number of quantification limit indicated by (<LD). The statistical difference is indicated as * < 0.05 vs. control, ** < 0.01 vs. control, *** < 0.001 vs. control, & < 0.05 vs. diabetic, && < 0.01 vs. diabetic.

4. Discussion

DR is considered a multifactorial disease [3]. In fact, it is difficult to understand the exact mechanisms by which diabetes induces DR due to its complex etiology. However, it is

well known that chronic exposure to hyperglycemia induces an increase in the production of reactive oxygen species with the subsequent loss of redox homeostasis, which notably contributes to early neuronal retinal cell death [3], pericytes demise, later rupture of the blood retinal barrier, increased vascular permeability [20] and the progression to advanced DR stages [20–22]. Delayed treatment of diabetes and cumulative molecular damage from oxidative stress led to the development of DR [23]. It has been shown that, after diagnosis of diabetes, strict and early control of blood glucose and/or dyslipidemia slows the evolution of this microangiopathy [24]. In spite of this, the treatment for DR is restricted to advanced stages of the disease when there are serious vascular alterations and the retina shows neuronal irreparable damages [3]. Therefore, it is imperative to find new strategies for early use to diagnose and prevent DR progression.

For the maintenance and development of the functions of the retina there are a series of essential molecular components such as molecules of long chain polyunsaturated fatty acids (PUFAs), which form part of the cell membranes. In fact, retinal membrane phospholipids contain the highest level of PUFA of any tissue. Specifically, docosahexaenoic acid (DHA; 22:6n-3), arachidonic acid (AA; 20:4n-6) and adrenic acid (22:4n-6) are the most abundant fatty acid in the retina [25–27]. Their physiological function include critical protective effects against different retinal diseases such as retinopathy of prematurity, age-related macular degeneration or DR [28]. For example, NPD1, a docosatriene derivative from docosahexaenoic acid, protects retinal epithelial cells from oxidative stress thanks to its anti-apoptotic effects [29], or their metabolism alteration by peroxisome dysfunction induces retinal defects [30].

Polyphenols are the most abundant antioxidants in the human diet [31] and their beneficial effects have prompted interest in their use for treating retinal pathologies. For example, a protective effect has been observed against DR and other retinopathies with curcumin [32,33], resveratrol [34–36], quercetin [37,38], epigallocatechin gallate [39,40], and Pter [7], among others. The all have one thing in common, their antioxidant capacity against oxidative stress after hypoxia [41,42] and their significant ability to stop the pathological angiogenesis [43] by reducing levels of the vascular endothelial growth factor (VEGF) [44]. It has therefore been suggested that polyphenolic administration can protect against the development of retinal diseases such as, DR.

Recently, we showed for the first time that daily Pter administration at non-toxic and biologically effective doses of 50 mg/kg can prevent the early neuro-retinal damage caused by hyperglycemia *in vivo* [7]. It is known that retinal neural cell death appears in early stages of the development of DR, even prior to the appearance of the classic phenotypic characteristics used in its diagnosis [7,45–47]. In addition, the increase of lipid peroxidation products has been associated with neurodegeneration diseases [48] and there is increasing evidence of the importance of products of lipid peroxidation as mediators in the development of neovascularization in DR [49,50]. In our previous study, we showed that Pter reduces the levels of 4-HNE [7], an end products of lipid peroxidation of PUFAs such as linoleic acid and arachidonic acid via non-enzymatic steps [27,51]. The low levels of 4-HNE induced by the polyphenol can reduce the former's damaging effects on proteins, RNA and DNA synthesis [52]. Moreover, Aguirre et al. showed that Pter mainly increases docosahexaenoic acid levels, although linoleic acid and arachidonic acid also increase without reaching statistical significance, indicating the ability of stilbene to restore the PUFA composition in a model of hepatic steatosis [53]. This ability of Pter could be relevant in the antioxidant protection observed in our experimental model.

The role of lipid peroxidation in DR has been extensively studied [54–56] but in a general way, focusing on the manifestation of a limited number of products such as MDA, 8-Iso-PGF_{2α} or 4-HNE, without focusing on the damage of omega-3 PUFA in such a specific way. Little is known about the effect of the protective role of polyphenols against radical induced peroxidation of omega-3 PUFAs by ROS related to neurodegeneration and its implication in the development of DR. In this research, an exhaustive study of the damage produced by oxidative stress in lipids of the retina was carried out. The components studied

can be classified depending on the modified lipid from which they are derived. We studied a group of products derived from the oxidation of arachidonic acid, docosahexaenoic acid, and adrenic acid (Figure 1). Spectrometry analyses showed that lipid peroxidation in the retinas of diabetic rabbits increased the levels of: PGE₂, PGF_{2α}, IsoPs 8-*iso*-PGE₂, 8-*iso*-15-keto-PGF_{2α}, and 8-*iso*-15-(*R*)-PGF_{2α}, 17-F_{2t}-dihomo-IsoP, Ent-7(*RS*)-7-F_{2t}-dihomo-IsoP, 17-*epi*-17-F_{2t}-dihomo-IsoP, 17(*RS*)-10-*epi*-SC-Δ¹⁵-11-dihomo-IsoF, 10-*epi*-10-F_{4t}-NeuroP, 4(*RS*)-4-F_{4t}-NeuroP, and 14(*RS*)-14-F_{4t}-NeuroP. The action of the natural polyphenol Pter was able to restore to control values the levels in diabetic rabbits (Figure 2).

The biological effect on DR of some of these compounds is well established and the protector role of this stilbene against DR progression has attracted much attention. The formation of prostaglandins, inflammatory mediators synthesized from arachidonic acid by cyclooxygenase enzyme (COX), such as PGE₂ and PGF_{2α} are associated with retinal vasoconstriction, blood ocular barrier disruption, VEGF production, increased vasodilation, leukocyte migration, and increased production of proinflammatory cytokines [49,57–61]. For example, the extracellular signal-regulated kinases 1 and 2 (ERK1/2)/COX-2/PGE₂ signaling pathway induces the expression of VEGF [49], whose overexpression is related to the vascular hyperpermeability and neovascularization developed in retinas of diabetic patients [3]. Moreover, progression of DR may be prevented or delayed by the use of prostaglandin inhibitors [49,50,62,63] and COX inhibitors reduce the production of VEGF, vascular leakage and neovascularization in DR and ischemic proliferative retinopathy in vivo [50,64].

Although the effects on DR have not been clearly identified in the present experimental model, from the set of compounds analyzed with significant differences and affected by Pter treatment we can make some interesting observations. 8-*iso*-15-Keto-PGF_{2α} is a metabolite of the 8-*iso*-PGF_{2α}, a prostaglandin-like product produced by the non-enzymatic peroxidation of arachidonic acid in membrane phospholipids [65] that showed vasoconstrictor effects in a concentration-dependent manner in rat aorta [66] and has been proposed as a biomarker for ischemic stroke diagnosis [67]. 8-*iso*-PGE₂ is also an isoprostane produced from arachidonic acid during lipid peroxidation [68] with renal vasoconstrictor effects in rat [68,69] and its urinary quantification is considered a reliable marker of systemic oxidative stress, even superior to its plasmatic evaluation [54]. Ent-7(*RS*)-7-F_{2t}-dihomo-IsoP, 17-*epi*-17-F_{2t}-dihomo-IsoP, 17-F_{2t}-dihomo-IsoP formed by a free radical non-enzymatic mechanism from adrenic acid (C22:4 n-6, AdA) [70] and, 10-*epi*-10-F_{4t}-NeuroP, 4(*RS*)-4-F_{4t}-NeuroP, and 14(*RS*)-14-F_{4t}-NeuroP by docosahexaenoic acid (C22:6 n-3, DHA) [71], have been used as biomarkers of oxidative stress in neurodegenerative disease [72–76]. Hence, although further research is necessary to clarify the pathophysiological action triggered by those PUFA derivatives in DR, Pter is able to normalize the levels of almost all analytes studied in retinas of diabetic rabbits, helping to protect the retina and avoiding the appearance of the very early signs of DR such as neuronal cell demise derived from oxidative stress.

Furthermore, the results presented allow us to hypothesize about the possible use of lipid peroxidation as an early biomarker of diabetic retinal disease. The diagnosis of DR and its ophthalmologic classification is based on the results of the multicenter Early Treatment Diabetic Retinopathy Study (ETDRS). This study classified DR in function of the visible ophthalmologic alterations and retinal neovascularization development [3,77,78]. There is no question of the usefulness of this diagnostic method in delaying disease progression to the sight loss. However, although the ophthalmologic diagnosis is minimally invasive, rapid and economical, the phenotypic manifestation of the disease involves the development of previous molecular unobservable alterations that trigger neuronal and vascular damage. Hence, because DR is an asymptomatic disease until reaching advanced stages, the identification of early diagnosis biomarkers could be the best tool to prevent the progression of the disease to an irreversible stage and ultimately the loss of vision. Therefore, analysis of these peroxidation lipid analytes at plasma and urine levels could instantly provide a clinical reflection of the oxidative status of patients before and after

specific clinical interventions. In Figures 3 and 4, a comparative study on lipid peroxidation analytes in plasma and urine samples between control, diabetic and Pter diabetic treated rabbits are shown. The oxidative environment induced by hyperglycemia together with the presence of skipped dienes makes PUFAs highly susceptible to oxidation [79,80]. PUFA-containing phospholipids react with reactive oxygen species generating a variety of oxidized products potentially harmful and capable of acting on targets located at a certain distance from the initial oxidative attack, since some of these products are more durable than reactive oxygen species [27,81]. Therefore, the measurement of concentrations of analytes of lipid peroxidation in biological samples is considered an important tool for evaluating the role of oxidative processes in the pathogenesis of human diseases and the response to specific therapies [16]. In addition, the study of these analytes in fluids such as plasma and urine can instantly provide a clinical reflection of the oxidative state and are useful in patients studies before and after specific clinical interventions (i.e., antioxidant treatment).

A number of published works indicate that oxidative stress caused by diabetes triggers lipid alterations with serious pathophysiological effects that contribute to the development of DR both in animal models [82] and in the retina of diabetic patients [83]. Moreover, patients suffering DR show higher lipid peroxidation than those without the retinal disease [84,85]. Although diabetes is associated with increased systemic oxidative stress, the present study demonstrates the ability of Pter to lower lipid peroxidation detected in plasma and urine and suggests new potential biomarkers to predict DR progression. Moreover, the results presented herein show a deeper and more extended lipid peroxidation study beyond the classic MDA or 4-HNE.

One of the most in vivo produced and studied F_2 -IsoP is 8-iso-PGF $_{2\alpha}$. In fact, it has been considered the gold standard biomarker of in vivo oxidative stress. However, we did not detect significant alterations in retina tissue (Figure 2). Different results were obtained from plasma and urine of diabetic rabbits, where levels of this F_2 -IsoP increased (Figures 3 and 4). Although 8-iso-PGF $_{2\alpha}$ is formed from arachidonic acid predominantly via non enzymatic oxidation, it can be generated by COX activity through the enzymatic oxidation of PGF $_{2\alpha}$ [86]. COX activity is ubiquitously induced in diabetic patients and F_2 -IsoPs have been involved in different acute and chronic human diseases related to oxidative and inflammatory stress such as diabetes [87]. This situation rules out considering 8-iso-PGF $_{2\alpha}$ as a suitable biomarker for DR.

One approach that could help support our hypothesis is to investigate the location of production of the different lipid peroxidation products studied. The products studied derived from arachidonic acid oxidation show a ubiquitous distribution in the body tissues, including retina [55]. The oxidation of docosahexaenoic acid and the production of NeuroP/neurofurans occurs mainly in brain grey matter and retina [71,88,89], and dihom-IsoP/dihomo-IsoF from adrenic acid oxidation are found in brain white matter and retina [15,70,90,91]. Furthermore, although it has not been studied in depth, docosahexaenoic and adrenic acid have been considered specific tissue markers of oxidative damage in neurological disorders such as Rett syndrome, Down syndrome, epilepsy, Alzheimer's disease and age-related macular degeneration [48,92]. Hence, we consider that lipid peroxidation compounds derived from docosahexaenoic and adrenic acid may be the most interesting analytes in the study of development and progression of DR. We detected parallel lipid peroxidation in retina and urine samples induced by hyperglycemia and the reinstatement to control values with the polyphenol treatment in 17- F_{2t} -dihomo-IsoP, Ent-7(RS)-7- F_{2t} -dihomo-IsoP, 17(RS)-10-*epi*-SC- Δ^{15} -11-dihomo-IsoF, 4(RS)-4- F_{4t} -NeuroP (Figures 2 and 4). In plasma and retina samples, we detected similar alterations just in 17(RS)-10-*epi*-SC- Δ^{15} -11-dihomo-IsoF and 10-*epi*-10- F_{4t} -NeuroP (Figures 2 and 3). Focusing on 17(RS)-10-*epi*-SC- Δ^{15} -11-dihomo-IsoF, which is derived from adrenic acid, this is increased in the retina, plasma and urine of diabetic rabbits and Pter is able to lower its concentration. Although further research with human samples in different DR evolution stages will help to corroborate its importance and its role, for the first time 17(RS)-10-*epi*-

SC- Δ^{15} -11-dihomo-IsoF is shown as a possible suitable biomarker of DR in the prevention of the development of the pathology.

5. Conclusions

Our study demonstrates the significant ability of Pter to prevent the retinal early lipid peroxidation induced in vivo by hyperglycemia, phenomenon determinant in the development and evolution of DR. A large group of specific neuronal and retinal lipid peroxidation markers was studied including derivatives from adrenic and docosaheptaenoic acid oxidation in plasma and urine samples. 17(RS)-10-*epi*-SC- Δ^{15} -11-dihomo-IsoF, a product derivative from adrenic acid oxidation, is postulated for the first time as an early DR biomarker. Further studies will be carried out with human samples at different stages of evolution to validate the usefulness of the determination of lipid peroxidation in plasma and/or urine in the diagnosis and staging of DR.

Author Contributions: Conceptualization, I.T.-C. and Á.L.O.; methodology, I.M., I.T.-C. and M.A.; standard synthesis C.O., J.-M.G. and T.D.; validation I.T.-C.; formal analysis, I.T.-C. and Á.L.O.; investigation, Á.L.O.; resources, M.V. and Á.L.O.; writing—original draft preparation, Á.L.O.; writing—review and editing, C.O., J.-M.G., T.D., I.T.-C. and Á.L.O.; visualization, I.T.-C., and Á.L.O.; supervision, Á.L.O.; project administration, Á.L.O.; funding acquisition, Á.L.O. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Ethics Committee for Animal Experimentation and Welfare of the University of Valencia (Spain) (ethical code number of animal use 2016/VSC/PEA/00198, Generalitat Valenciana, 18 October 2016).

Informed Consent Statement: Not applicable.

Data Availability Statement: The data presented in this study are available within the article.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Nigel Unwin, D.G.; Mbanya, J.C.; Ramachandran, A.; Roglic, G.; Shaw, J.; Soltész, G.; Whiting, D.; Zgibor, J.; Zhang, P.; Zimmet, P.; et al. IDF Diabetes Atlas Fourth Edition. Available online: www.eatlas.idf.org (accessed on 10 December 2020).
2. Saeedi, P.; Petersohn, I.; Salpea, P.; Malanda, B.; Karuranga, S.; Unwin, N.; Colagiuri, S.; Guariguata, L.; Motala, A.A.; Ogurtsova, K.; et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. *Diabetes Res. Clin. Pract.* **2019**. [CrossRef]
3. Rodríguez, M.L.; Pérez, S.; Mena-Mollá, S.; Desco, M.C.; Ortega, Á.L. Oxidative Stress and Microvascular Alterations in Diabetic Retinopathy: Future Therapies. *Oxid. Med. Cell Longev.* **2019**, *2019*, 18. [CrossRef]
4. Wangsa-Wirawan, N.D.; Linsenmeier, R.A. Retinal oxygen: Fundamental and clinical aspects. *Arch. Ophthalmol.* **2003**, *121*, 547–557. [CrossRef]
5. Testa, R.; Bonfigli, A.R.; Prattichizzo, F.; La Sala, L.; De Nigris, V.; Ceriello, A. The “Metabolic Memory” Theory and the Early Treatment of Hyperglycemia in Prevention of Diabetic Complications. *Nutrients* **2017**, *9*, 437. [CrossRef] [PubMed]
6. Laddha, A.P.; Kulkarni, Y.A. Tannins and vascular complications of Diabetes: An update. *Phytomedicine* **2019**, *56*, 229–245. [CrossRef] [PubMed]
7. Millán, I.; Desco, M.D.C.; Torres-Cuevas, I.; Pérez, S.; Pulido, I.; Mena-Mollá, S.; Mataix, J.; Asensi, M.; Ortega, Á.L. Pterostilbene prevents early diabetic retinopathy alterations in a rabbit experimental model. *Nutrients* **2020**, *12*, 82. [CrossRef]
8. Dodda, D.; Rama Rao, A.; Veeresham, C. In vitro and in vivo evaluation of pterostilbene for the management of diabetic complications. *J. Ayurveda Integr. Med.* **2020**, *11*, 369–375. [CrossRef] [PubMed]
9. Thangasamy, G.; Pari, L. Protective role of pterostilbene on plasma and tissue glycoprotein components in high-fat diet-fed and streptozotocin-induced type 2 diabetic mice. *Asian J. Pharm. Clin. Res.* **2019**, *12*, 4. [CrossRef]
10. Berdeaux, O.; Acar, N. Very-long-chain polyunsaturated fatty acids in the retina: Analysis and clinical relevance in physiological and pathological conditions. *Oilseeds Fat Crops Lipids* **2011**, *18*, 7. [CrossRef]
11. Agbaga, M.P.; Mandal, M.N.; Anderson, R.E. Retinal very long-chain PUFAs: New insights from studies on ELOVL4 protein. *J. Lipid Res.* **2010**, *51*, 1624–1642. [CrossRef]
12. Stahl, A.; Krohne, T.U.; Sapieha, P.; Chen, J.; Hellstrom, A.; Chew, E.; Holz, F.G.; Smith, L.E. Lipid metabolites in the pathogenesis and treatment of neovascular eye disease. *Br. J. Ophthalmol.* **2011**, *95*, 1496–1501. [CrossRef] [PubMed]

13. Krohne, T.U.; Stratmann, N.K.; Kopitz, J.; Holz, F.G. Effects of lipid peroxidation products on lipofuscinogenesis and autophagy in human retinal pigment epithelial cells. *Exp. Eye Res.* **2010**, *90*, 465–471. [[CrossRef](#)] [[PubMed](#)]
14. Alabadí, J.A.; Miranda, F.J.; Lloréns, S.; Centeno, J.M.; Marrachelli, V.G.; Alborch, E. Mechanisms underlying diabetes enhancement of endothelin-1-induced contraction in rabbit basilar artery. *Eur. J. Pharmacol.* **2004**, *486*, 289–296. [[CrossRef](#)] [[PubMed](#)]
15. De la Torre, A.; Lee, Y.Y.; Mazzoni, A.; Guy, A.; Bultel-Poncé, V.; Durand, T.; Oger, C.; Lee, J.C.; Galano, J.M. Total syntheses and in vivo quantitation of novel neurofuran and dihomio-isofuran derived from docosahexaenoic acid and adrenic acid. *Chemistry* **2015**, *21*, 2442–2446. [[CrossRef](#)] [[PubMed](#)]
16. Cháfer-Pericás, C.; Rahkonen, L.; Sánchez-Illana, A.; Kuligowski, J.; Torres-Cuevas, I.; Cernada, M.; Cubells, E.; Nuñez-Ramiro, A.; Andersson, S.; Vento, M.; et al. Ultra high performance liquid chromatography coupled to tandem mass spectrometry determination of lipid peroxidation biomarkers in newborn serum samples. *Anal. Chim. Acta* **2015**, *886*, 214–220. [[CrossRef](#)]
17. Bioanalytical Method Validation. *Guidance for Industry*; US Department of Health and Human Services; Food and Drug Administration (FDA); Center for Drug Evaluation and Research (CDER); Center for Veterinary Medicine (CVM); Silver Spring: Montgomery County, MD, USA, 2018; p. 44. Available online: <http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm> (accessed on 10 December 2020).
18. García-Blanco, A.; Peña-Bautista, C.; Oger, C.; Vigor, C.; Galano, J.M.; Durand, T.; Martín-Ibáñez, N.; Baquero, M.; Vento, M.; Cháfer-Pericás, C. Reliable determination of new lipid peroxidation compounds as potential early Alzheimer Disease biomarkers. *Talanta* **2018**, *184*, 193–201. [[CrossRef](#)]
19. Kuligowski, J.; Escobar, J.; Quintás, G.; Lliso, I.; Torres-Cuevas, I.; Nuñez, A.; Cubells, E.; Rook, D.; van Goudoever, J.B.; Vento, M. Analysis of lipid peroxidation biomarkers in extremely low gestational age neonate urines by UPLC-MS/MS. *Anal. Bioanal. Chem.* **2014**, *406*, 4345–4356. [[CrossRef](#)]
20. Semeraro, F.; Morescalchi, F.; Cancarini, A.; Russo, A.; Rezzola, S.; Costagliola, C. Diabetic retinopathy, a vascular and inflammatory disease: Therapeutic implications. *Diabetes Metab.* **2019**, *45*, 517–527. [[CrossRef](#)]
21. Ahsan, H. Diabetic retinopathy—biomolecules and multiple pathophysiology. *Diabetes Metab. Syndr.* **2014**, *9*, 51–54. [[CrossRef](#)]
22. Rangasamy, S.; McGuire, P.G.; Das, A. Diabetic retinopathy and inflammation: Novel therapeutic targets. *Middle East Afr. J. Ophthalmol.* **2012**, *19*, 52–59. [[CrossRef](#)]
23. Ishida, S.; Usui, T.; Yamashiro, K.; Kaji, Y.; Ahmed, E.; Carrasquillo, K.G.; Amano, S.; Hida, T.; Oguchi, Y.; Adamis, A.P. VEGF164 is proinflammatory in the diabetic retina. *Investig. Ophthalmol. Vis. Sci.* **2003**, *44*, 2155–2162. [[CrossRef](#)]
24. Chew, E.Y.; Ambrosius, W.T.; Davis, M.D.; Danis, R.P.; Gangaputra, S.; Greven, C.M.; Hubbard, L.; Esser, B.A.; Lovato, J.F.; Perdue, L.H.; et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. *N. Engl. J. Med.* **2010**, *363*, 233–244. [[CrossRef](#)] [[PubMed](#)]
25. Martinez, M. Tissue levels of polyunsaturated fatty acids during early human development. *J. Pediatr.* **1992**, *120*, S129–S138. [[CrossRef](#)]
26. Liu, A.; Chang, J.; Lin, Y.; Shen, Z.; Bernstein, P.S. Long-chain and very long-chain polyunsaturated fatty acids in ocular aging and age-related macular degeneration. *J. Lipid. Res.* **2010**, *51*, 3217–3229. [[CrossRef](#)] [[PubMed](#)]
27. Tanito, M.; Anderson, R.E. Dual roles of polyunsaturated fatty acids in retinal physiology and pathophysiology associated with retinal degeneration. *Clin. Lipidol.* **2009**, *4*, 7. [[CrossRef](#)]
28. Suzumura, A.; Terao, R.; Kaneko, H. Protective Effects and Molecular Signaling of n-3 Fatty Acids on Oxidative Stress and Inflammation in Retinal Diseases. *Antioxid. Basel* **2020**, *9*, 920. [[CrossRef](#)]
29. Behl, T.; Kotwani, A. Omega-3 fatty acids in prevention of diabetic retinopathy. *J. Pharm. Pharmacol.* **2017**, *69*, 946–954. [[CrossRef](#)] [[PubMed](#)]
30. Das, Y.; Roose, N.; De Groef, L.; Fransen, M.; Moons, L.; Van Veldhoven, P.P.; Baes, M. Differential distribution of peroxisomal proteins points to specific roles of peroxisomes in the murine retina. *Mol. Cell Biochem.* **2019**, *456*, 53–62. [[CrossRef](#)]
31. Scalbert, A.; Johnson, I.T.; Saltmarsh, M. Polyphenols: Antioxidants and beyond. *Am. J. Clin. Nutr.* **2005**, *81*, 215S–217S. [[CrossRef](#)]
32. Chang, Y.C.; Chang, W.C.; Hung, K.H.; Yang, D.M.; Cheng, Y.H.; Liao, Y.W.; Woung, L.C.; Tsai, C.Y.; Hsu, C.C.; Lin, T.C.; et al. The generation of induced pluripotent stem cells for macular degeneration as a drug screening platform: Identification of curcumin as a protective agent for retinal pigment epithelial cells against oxidative stress. *Front. Aging Neurosci.* **2014**, *6*, 191. [[CrossRef](#)]
33. Kowluru, R.A.; Kanwar, M. Effects of curcumin on retinal oxidative stress and inflammation in diabetes. *Nutr. Metab. Lond.* **2007**, *4*, 8. [[CrossRef](#)] [[PubMed](#)]
34. Soufi, F.G.; Mohammad-Nejad, D.; Ahmadi, H. Resveratrol improves diabetic retinopathy possibly through oxidative stress—Nuclear factor κ B—Apoptosis pathway. *Pharmacol. Rep.* **2012**, *64*, 1505–1514. [[CrossRef](#)]
35. Li, W.; Jiang, D. Effect of resveratrol on Bcl-2 and VEGF expression in oxygen-induced retinopathy of prematurity. *J. Pediatr. Ophthalmol. Strabismus* **2012**, *49*, 230–235. [[CrossRef](#)] [[PubMed](#)]
36. Nagineni, C.N.; Raju, R.; Nagineni, K.K.; Kommineni, V.K.; Cherukuri, A.; Kutty, R.K.; Hooks, J.J.; Detrick, B. Resveratrol Suppresses Expression of VEGF by Human Retinal Pigment Epithelial Cells: Potential Nutraceutical for Age-related Macular Degeneration. *Aging Dis.* **2014**, *5*, 88–100. [[CrossRef](#)]
37. Zhuang, P.; Shen, Y.; Lin, B.Q.; Zhang, W.Y.; Chiou, G.C. Effect of quercetin on formation of choroidal neovascularization (CNV) in age-related macular degeneration (AMD). *Eye Sci.* **2011**, *26*, 23–29. [[CrossRef](#)]

38. Kumar, B.; Gupta, S.K.; Nag, T.C.; Srivastava, S.; Saxena, R.; Jha, K.A.; Srinivasan, B.P. Retinal neuroprotective effects of quercetin in streptozotocin-induced diabetic rats. *Exp. Eye Res.* **2014**, *125*, 193–202. [[CrossRef](#)]
39. Silva, K.C.; Rosales, M.A.; Hamassaki, D.E.; Saito, K.C.; Faria, A.M.; Ribeiro, P.A.; Faria, J.B.; Faria, J.M. Green tea is neuroprotective in diabetic retinopathy. *Investig. Ophthalmol. Vis. Sci.* **2013**, *54*, 1325–1336. [[CrossRef](#)]
40. Lee, H.S.; Jun, J.H.; Jung, E.H.; Koo, B.A.; Kim, Y.S. Epigallocatechin-3-gallate inhibits ocular neovascularization and vascular permeability in human retinal pigment epithelial and human retinal microvascular endothelial cells via suppression of MMP-9 and VEGF activation. *Molecules* **2014**, *19*, 12150–12172. [[CrossRef](#)]
41. Liu, X.Q.; Wu, B.J.; Pan, W.H.; Zhang, X.M.; Liu, J.H.; Chen, M.M.; Chao, F.P.; Chao, H.M. Resveratrol mitigates rat retinal ischemic injury: The roles of matrix metalloproteinase-9, inducible nitric oxide, and heme oxygenase-1. *J. Ocul. Pharmacol. Ther.* **2012**, *29*, 33–40. [[CrossRef](#)]
42. Agrawal, M.; Kumar, V.; Singh, A.K.; Kashyap, M.P.; Khanna, V.K.; Siddiqui, M.A.; Pant, A.B. trans-Resveratrol protects ischemic PC12 Cells by inhibiting the hypoxia associated transcription factors and increasing the levels of antioxidant defense enzymes. *ACS Chem. Neurosci.* **2013**, *4*, 285–294. [[CrossRef](#)]
43. Arjamaa, O.; Nikinmaa, M. Oxygen-dependent diseases in the retina: Role of hypoxia-inducible factors. *Exp. Eye Res.* **2006**, *83*, 473–483. [[CrossRef](#)] [[PubMed](#)]
44. Campochiaro, P.A. Retinal and choroidal neovascularization. *J. Cell Physiol.* **2000**, *184*, 301–310. [[CrossRef](#)]
45. El-Fayoumi, D.; Badr Eldine, N.M.; Esmael, A.F.; Ghalwash, D.; Soliman, H.M. Retinal Nerve Fiber Layer and Ganglion Cell Complex Thicknesses Are Reduced in Children With Type 1 Diabetes With No Evidence of Vascular Retinopathy. *Investig. Ophthalmol. Vis. Sci.* **2016**, *57*, 5355–5360. [[CrossRef](#)] [[PubMed](#)]
46. Van Dijk, H.W.; Verbraak, F.D.; Kok, P.H.; Garvin, M.K.; Sonka, M.; Lee, K.; Devries, J.H.; Michels, R.P.; van Velthoven, M.E.; Schlingemann, R.O.; et al. Decreased retinal ganglion cell layer thickness in patients with type 1 diabetes. *Investig. Ophthalmol. Vis. Sci.* **2010**, *51*, 3660–3665. [[CrossRef](#)] [[PubMed](#)]
47. Zhang, C.; Xu, Y.; Tan, H.Y.; Li, S.; Wang, N.; Zhang, Y.; Feng, Y. Neuroprotective effect of He-Ying-Qing-Re formula on retinal ganglion cell in diabetic retinopathy. *J. Ethnopharmacol.* **2018**, *214*, 179–189. [[CrossRef](#)] [[PubMed](#)]
48. Signorini, C.; De Felice, C.; Galano, J.M.; Oger, C.; Leoncini, S.; Cortelazzo, A.; Ciccoli, L.; Durand, T.; Hayek, J.; Lee, J.C. Isoprostanoids in Clinical and Experimental Neurological Disease Models. *Antioxidants* **2018**, *7*, 88. [[CrossRef](#)] [[PubMed](#)]
49. Li, T.; Hu, J.; Du, S.; Chen, Y.; Wang, S.; Wu, Q. ERK1/2/COX-2/PGE2 signaling pathway mediates GPR91-dependent VEGF release in streptozotocin-induced diabetes. *Mol. Vis.* **2014**, *20*, 1109–1121.
50. Ayalasmayajula, S.P.; Kompella, U.B. Celecoxib, a selective cyclooxygenase-2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin-induced diabetic rat model. *Eur. J. Pharmacol.* **2003**, *458*, 283–289. [[CrossRef](#)]
51. Esterbauer, H. Cytotoxicity and genotoxicity of lipid-oxidation products. *Am. J. Clin. Nutr.* **1993**, *57*, 779S–785S. [[CrossRef](#)]
52. Csala, M.; Kardon, T.; Legeza, B.; Lizák, B.; Mandl, J.; Margittai, É.; Puskás, F.; Száraz, P.; Szelényi, P.; Bánhegyi, G. On the role of 4-hydroxynonenal in health and disease. *Biochim. Biophys Acta* **2015**, *1852*, 826–838. [[CrossRef](#)]
53. Aguirre, L.; Palacios-Ortega, S.; Fernández-Quintela, A.; Hijona, E.; Bujanda, L.; Portillo, M.P. Pterostilbene Reduces Liver Steatosis and Modifies Hepatic Fatty Acid Profile in Obese Rats. *Nutrients* **2019**, *11*, 961. [[CrossRef](#)]
54. Al-Shabrawey, M.; Smith, S. Prediction of diabetic retinopathy: Role of oxidative stress and relevance of apoptotic biomarkers. *EPMA J.* **2010**, *1*, 56–72. [[CrossRef](#)] [[PubMed](#)]
55. Njie-Mbye, Y.F.; Kulkarni-Chitnis, M.; Opere, C.A.; Barrett, A.; Ohia, S.E. Lipid peroxidation: Pathophysiological and pharmacological implications in the eye. *Front. Physiol.* **2013**, *4*, 366. [[CrossRef](#)] [[PubMed](#)]
56. Tangvarasittichai, O.; Tangvarasittichai, S. Oxidative Stress, Ocular Disease and Diabetes Retinopathy. *Curr. Pharm. Des.* **2018**, *24*, 4726–4741. [[CrossRef](#)]
57. Wang, M.H.; Hsiao, G.; Al-Shabrawey, M. Eicosanoids and Oxidative Stress in Diabetic Retinopathy. *Antioxidants* **2020**, *9*, 520. [[CrossRef](#)]
58. Kim, S.J.; Flach, A.J.; Jampol, L.M. Nonsteroidal anti-inflammatory drugs in ophthalmology. *Surv. Ophthalmol.* **2010**, *55*, 108–133. [[CrossRef](#)]
59. Cheng, T.; Cao, W.; Wen, R.; Steinberg, R.H.; LaVail, M.M. Prostaglandin E2 induces vascular endothelial growth factor and basic fibroblast growth factor mRNA expression in cultured rat Müller cells. *Investig. Ophthalmol. Vis. Sci.* **1998**, *39*, 581–591.
60. Kim, S.J.; Toma, H.S.; Barnett, J.M.; Penn, J.S. Ketorolac inhibits choroidal neovascularization by suppression of retinal VEGF. *Exp. Eye Res.* **2010**, *91*, 537–543. [[CrossRef](#)]
61. Schoenberger, S.D.; Kim, S.J.; Sheng, J.; Rezaei, K.A.; Lalezary, M.; Cherney, E. Increased prostaglandin E2 (PGE2) levels in proliferative diabetic retinopathy, and correlation with VEGF and inflammatory cytokines. *Investig. Ophthalmol. Vis. Sci.* **2012**, *53*, 5906–5911. [[CrossRef](#)]
62. Kern, T.S.; Miller, C.M.; Du, Y.; Zheng, L.; Mohr, S.; Ball, S.L.; Kim, M.; Jamison, J.A.; Bingaman, D.P. Topical administration of nepafenac inhibits diabetes-induced retinal microvascular disease and underlying abnormalities of retinal metabolism and physiology. *Diabetes* **2007**, *56*, 373–379. [[CrossRef](#)]
63. Joussen, A.M.; Poulaki, V.; Mitsiades, N.; Kirchhof, B.; Koizumi, K.; Döhmen, S.; Adamis, A.P. Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. *FASEB J.* **2002**, *16*, 438–440. [[CrossRef](#)] [[PubMed](#)]

64. Sennlaub, F.; Valamanesh, F.; Vazquez-Tello, A.; El-Asrar, A.M.; Checchin, D.; Brault, S.; Gobeil, F.; Beauchamp, M.H.; Mwaikambo, B.; Courtois, Y.; et al. Cyclooxygenase-2 in human and experimental ischemic proliferative retinopathy. *Circulation* **2003**, *108*, 198–204. [[CrossRef](#)] [[PubMed](#)]
65. Morrow, J.D.; Hill, K.E.; Burk, R.F.; Nammour, T.M.; Badr, K.F.; Roberts, L.J. A series of prostaglandin F₂-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. *Proc. Natl. Acad. Sci. USA* **1990**, *87*, 9383–9387. [[CrossRef](#)]
66. Cracowski, J.L.; Camus, L.; Durand, T.; Devillier, P.; Guy, A.; Hardy, G.; Stanke-Labesque, F.; Rossi, J.C.; Bessard, G. Response of rat thoracic aorta to F(2)-isoprostane metabolites. *J. Cardiovasc. Pharmacol.* **2002**, *39*, 396–403. [[CrossRef](#)] [[PubMed](#)]
67. Zhang, L.; Ma, F.; Qi, A.; Liu, L.; Zhang, J.; Xu, S.; Zhong, Q.; Chen, Y.; Zhang, C.Y.; Cai, C. Integration of ultra-high-pressure liquid chromatography-tandem mass spectrometry with machine learning for identifying fatty acid metabolite biomarkers of ischemic stroke. *Chem. Commun. Camb.* **2020**, *56*, 6656–6659. [[CrossRef](#)]
68. Morrow, J.D.; Minton, T.A.; Mukundan, C.R.; Campbell, M.D.; Zackert, W.E.; Daniel, V.C.; Badr, K.F.; Blair, I.A.; Roberts, L.J. Free radical-induced generation of isoprostanes in vivo. Evidence for the formation of D-ring and E-ring isoprostanes. *J. Biol. Chem.* **1994**, *269*, 4317–4326. [[CrossRef](#)]
69. Longmire, A.W.; Roberts, L.J.; Morrow, J.D. Actions of the E₂-isoprostane, 8-ISO-PGE₂, on the platelet thromboxane/endoperoxide receptor in humans and rats: Additional evidence for the existence of a unique isoprostane receptor. *Prostaglandins* **1994**, *48*, 247–256. [[CrossRef](#)]
70. VanRollins, M.; Woltjer, R.L.; Yin, H.; Morrow, J.D.; Montine, T.J. F₂-dihomo-isoprostanes arise from free radical attack on adrenic acid. *J. Lipid Res.* **2008**, *49*, 995–1005. [[CrossRef](#)]
71. Roberts, L.J.; Montine, T.J.; Markesbery, W.R.; Tapper, A.R.; Hardy, P.; Chemtob, S.; Dettbarn, W.D.; Morrow, J.D. Formation of isoprostane-like compounds (neuroprostanes) in vivo from docosahexaenoic acid. *J. Biol. Chem.* **1998**, *273*, 13605–13612. [[CrossRef](#)]
72. Medina, S.; Carrasco-Torres, R.; Amor, I.; Oger, C.; Galano, J.-M.; Durand, T.; Villegas Martínez, I.; Auvin, S.; Ferreres, F.; Gil-Izquierdo, Á. Antiepileptic drugs affect lipid oxidative markers- neuroprostanes and F₂-dihomo-isoprostanes- in patients with epilepsy: Differences among first-, second-, and third-generation drugs by UHPLC-QqQ-MS/MS. *RSC Adv.* **2016**, *6*, 8. [[CrossRef](#)]
73. Medina, S.; Miguel-Elizaga, I.D.; Oger, C.; Galano, J.M.; Durand, T.; Martínez-Villanueva, M.; Castillo, M.L.; Villegas-Martínez, I.; Ferreres, F.; Martínez-Hernández, P.; et al. Dihomo-isoprostanes-nonenzymatic metabolites of AdA-are higher in epileptic patients compared to healthy individuals by a new ultrahigh pressure liquid chromatography-triple quadrupole-tandem mass spectrometry method. *Free Radic Biol. Med.* **2015**, *79*, 154–163. [[CrossRef](#)] [[PubMed](#)]
74. García-Flores, L.A.; Medina, S.; Martínez-Hernández, P.; Oger, C.; Galano, J.M.; Durand, T.; Casas-Pina, T.; Ferreres, F.; Gil-Izquierdo, Á. Snapshot situation of oxidative degradation of the nervous system, kidney, and adrenal glands biomarkers- neuroprostaglandin and dihomoisoprostanes-urinary biomarkers from infancy to elderly adults. *Redox Biol.* **2017**, *11*, 586–591. [[CrossRef](#)] [[PubMed](#)]
75. Peña-Bautista, C.; Carrascosa-Marco, P.; Oger, C.; Vigor, C.; Galano, J.M.; Durand, T.; Baquero, M.; López-Nogueroles, M.; Vento, M.; García-Blanco, A.; et al. Validated analytical method to determine new salivary lipid peroxidation compounds as potential neurodegenerative biomarkers. *J. Pharm. Biomed. Anal.* **2019**, *164*, 742–749. [[CrossRef](#)] [[PubMed](#)]
76. Peña-Bautista, C.; Álvarez, L.; Durand, T.; Vigor, C.; Cuevas, A.; Baquero, M.; Vento, M.; Hervás, D.; Cháfer-Pericás, C. Clinical Utility of Plasma Lipid Peroxidation Biomarkers in Alzheimer's Disease Differential Diagnosis. *Antioxidants* **2020**, *9*, 649. [[CrossRef](#)] [[PubMed](#)]
77. Wilkinson, C.P.; Ferris, F.L.; Klein, R.E.; Lee, P.P.; Agardh, C.D.; Davis, M.; Dills, D.; Kampik, A.; Pararajasegaram, R.; Verdager, J.T.; et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. *Ophthalmology* **2003**. [[CrossRef](#)]
78. Early Photocoagulation for Diabetic Retinopathy: ETDRS Report Number 9. *Ophthalmology* **1991**. [[CrossRef](#)]
79. Kersten, E.; Paun, C.C.; Schellevis, R.L.; Hoyng, C.B.; Delcourt, C.; Lengyel, I.; Peto, T.; Ueffing, M.; Klaver, C.C.W.; Dammeier, S.; et al. Systemic and ocular fluid compounds as potential biomarkers in age-related macular degeneration. *Surv. Ophthalmol.* **2018**, *63*, 9–39. [[CrossRef](#)]
80. Cai, J.; Nelson, K.C.; Wu, M.; Sternberg, P.; Jones, D.P. Oxidative damage and protection of the RPE. *Prog. Retin. Eye Res.* **2000**, *19*, 205–221. [[CrossRef](#)]
81. Galano, J.M.; Lee, Y.Y.; Oger, C.; Vigor, C.; Vercauteren, J.; Durand, T.; Giera, M.; Lee, J.C. Isoprostanes, neuroprostanes and phytoprostanes: An overview of 25years of research in chemistry and biology. *Prog. Lipid Res.* **2017**, *68*, 83–108. [[CrossRef](#)]
82. Al-Shabrawey, M.; Bartoli, M.; El-Remessy, A.B.; Ma, G.; Matragoon, S.; Lemtalsi, T.; Caldwell, R.W.; Caldwell, R.B. Role of NADPH oxidase and Stat3 in statin-mediated protection against diabetic retinopathy. *Investig. Ophthalmol. Vis. Sci.* **2008**, *49*, 3231–3238. [[CrossRef](#)]
83. Davì, G.; Ciabattoni, G.; Consoli, A.; Mezzetti, A.; Falco, A.; Santarone, S.; Pennese, E.; Vitacolonna, E.; Bucciarelli, T.; Costantini, F.; et al. In vivo formation of 8-iso-prostaglandin f₂alpha and platelet activation in diabetes mellitus: Effects of improved metabolic control and vitamin E supplementation. *Circulation* **1999**, *99*, 224–229. [[CrossRef](#)] [[PubMed](#)]
84. Mondal, L.K.; Bhaduri, G.; Bhattacharya, B. Biochemical scenario behind initiation of diabetic retinopathy in type 2 diabetes mellitus. *Indian. J. Ophthalmol.* **2018**, *66*, 535–540. [[CrossRef](#)] [[PubMed](#)]

85. Polak, M.; Zagórski, Z. Lipid peroxidation in diabetic retinopathy. *Ann. Univ. Mariae Curie Skłodowska Med.* **2004**, *59*, 434–437. [[PubMed](#)]
86. Van't Erve, T.J.; Lih, F.B.; Jelsema, C.; Deterding, L.J.; Eling, T.E.; Mason, R.P.; Kadiiska, M.B. Reinterpreting the best biomarker of oxidative stress: The 8-iso-prostaglandin F_{2α}/prostaglandin F_{2α} ratio shows complex origins of lipid peroxidation biomarkers in animal models. *Free Radic. Biol. Med.* **2016**, *95*, 65–73. [[CrossRef](#)] [[PubMed](#)]
87. Milne, G.L.; Musiek, E.S.; Morrow, J.D. F2-isoprostanes as markers of oxidative stress in vivo: An overview. *Biomarkers* **2005**, *10* (Suppl. 1), S10–S23. [[CrossRef](#)] [[PubMed](#)]
88. Nourooz-Zadeh, J.; Liu, E.H.; Anggård, E.; Halliwell, B. F4-isoprostanes: A novel class of prostanoids formed during peroxidation of docosahexaenoic acid (DHA). *Biochem. Biophys. Res. Commun.* **1998**, *242*, 338–344. [[CrossRef](#)] [[PubMed](#)]
89. Fessel, J.P.; Porter, N.A.; Moore, K.P.; Sheller, J.R.; Roberts, L.J. Discovery of lipid peroxidation products formed in vivo with a substituted tetrahydrofuran ring (isofurans) that are favored by increased oxygen tension. *Proc. Natl. Acad. Sci. USA* **2002**, *99*, 16713–16718. [[CrossRef](#)] [[PubMed](#)]
90. De La Torre, A.; Lee, Y.Y.; Oger, C.; Sangild, P.T.; Durand, T.; Lee, J.C.; Galano, J.M. Synthesis, discovery, and quantitation of dihomom-isofurans: Biomarkers for in vivo adrenic acid peroxidation. *Angew. Chem. Int. Ed. Engl.* **2014**, *53*, 6249–6252. [[CrossRef](#)]
91. Song, W.L.; Lawson, J.A.; Reilly, D.; Rokach, J.; Chang, C.T.; Giasson, B.; FitzGerald, G.A. Neurofurans, novel indices of oxidant stress derived from docosahexaenoic acid. *J. Biol. Chem.* **2008**, *283*, 6–16. [[CrossRef](#)]
92. Leung, H.H.; Ng, A.L.; Durand, T.; Kawasaki, R.; Oger, C.; Balas, L.; Galano, J.M.; Wong, I.Y.; Chung-Yung Lee, J. Increase in omega-6 and decrease in omega-3 polyunsaturated fatty acid oxidation elevates the risk of exudative AMD development in adults with Chinese diet. *Free Radic. Biol. Med.* **2019**, *145*, 349–356. [[CrossRef](#)]